Veru Inc. (VERU)
0.58
-0.03 (-5.10%)
At close: Jan 30, 2025, 3:59 PM
0.58
0.10%
After-hours Jan 30, 2025, 06:47 PM EST
undefined% (undefined)
| Bid | 0.58 |
| Market Cap | 85.53M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.28 |
| PE Ratio (ttm) | -2.09 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.58 |
| Volume | 4,404,911 |
| Avg. Volume (20D) | 2,794,433 |
| Open | 0.60 |
| Previous Close | 0.61 |
| Day's Range | 0.55 - 0.61 |
| 52-Week Range | 0.36 - 1.92 |
| Beta | undefined |
About VERU
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 11, 1999
Employees 189
Stock Exchange NASDAQ
Ticker Symbol VERU
Website https://www.verupharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for VERU stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 584.58% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Veru Inc. is scheduled to release its earnings on Feb 10, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+2.36%
Veru shares are trading higher after the company a...
Unlock content with
Pro Subscription
10 months ago
+8.27%
Veru shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and a price target of $3.
